The "HP PRO SOLUTION" has received U.S. Food and Drug Administration 510 (k) clearance.

The "HP PRO SOLUTION", has been designed and developed by Orfit’s in house R&D Group with input from leading experts. HP PRO meets and exceeds the very demanding specifications and requirements associated with Proton Therapy. When used with Orfit’s cutting edge ultra-thin and stable Nanor immobilization masks, based on nanotechnology, HP PRO offers a unique combination of High Precision immobilization and patient comfort.

The British Royal Infirmary, a leading hospital in Bristol (UK), has recently introduced a new gamma knife treatment using the Orfit radiotherapy mask.

HP PRO hardware is designed for use in both Proton and Photon Therapy providing important versatility. The products are homogenous, low density, lightweight and available in a range of configurations including Overlays, Extensions and a combination Overlay/Extension in one product. A full range of accessories including patient customized head rests is available.

"Ensuring Patient comfort has always been and continues to be one of our major priorities. We firmly believe that the Orfit ‘HP PRO SOLUTION’, used in combination with our nanotechnology-based masks, will help alleviate discomfort and anxiety which is especially important when treating children," said Steven Cuypers, CEO of Orfit.

One of the world leading cancer centers based in the U.S. has recently selected Orfit’s "HP PRO SOLUTION" for use in their new proton center which is scheduled to start treating patients very soon.

Orfit Industries, with headquarters in Antwerp (Belgium), a family-owned business, is a world market leader in the development and manufacturing of low temperature thermoplastics, hardware and accessories for patient immobilization and positioning in Radiation Oncology.

In addition, Orfit manufactures thermoplastic materials for Physical Rehabilitation (Splinting) and Technical Orthopedics markets. The company exports its products to 104 countries. Each year, Orfit re-invests up to 15% of its turnover in R&D